These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 32437068

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. ESR1-Stabilizing Long Noncoding RNA TMPO-AS1 Promotes Hormone-Refractory Breast Cancer Progression.
    Mitobe Y, Ikeda K, Suzuki T, Takagi K, Kawabata H, Horie-Inoue K, Inoue S.
    Mol Cell Biol; 2019 Dec 01; 39(23):. PubMed ID: 31501276
    [Abstract] [Full Text] [Related]

  • 3. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis.
    Wang R, Huang Z, Qian C, Wang M, Zheng Y, Jiang R, Yu C.
    Biochem Biophys Res Commun; 2020 Jun 11; 526(4):1005-1012. PubMed ID: 32307083
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis.
    Han C, Fu Y, Zeng N, Yin J, Li Q.
    Aging (Albany NY); 2020 Feb 17; 12(4):3594-3616. PubMed ID: 32074085
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression.
    Zhang X, Zhou Y, Mao F, Lin Y, Shen S, Sun Q.
    Sci Rep; 2020 May 06; 10(1):7662. PubMed ID: 32376943
    [Abstract] [Full Text] [Related]

  • 9. LncRNA TMPO-AS1 promotes LCN2 transcriptional activity and exerts oncogenic functions in ovarian cancer.
    Zhao H, Ding F, Zheng G.
    FASEB J; 2020 Sep 06; 34(9):11382-11394. PubMed ID: 32692467
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
    Fan CN, Ma L, Liu N.
    J Cell Biochem; 2019 Mar 06; 120(3):3185-3196. PubMed ID: 30203490
    [Abstract] [Full Text] [Related]

  • 12. Overexpression and Clinicopathological Correlation of Long Noncoding RNA TMPO-AS1 in Colorectal Cancer Patients.
    Mohammadrezakhani H, Baradaran B, Shanehbandi D, Asadi M, Hashemzadeh S, Hajiasgharzadeh K, Safaralizadeh R.
    J Gastrointest Cancer; 2020 Sep 06; 51(3):952-956. PubMed ID: 31768869
    [Abstract] [Full Text] [Related]

  • 13. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer.
    Wu J, Xu W, Ma L, Sheng J, Ye M, Chen H, Zhang Y, Wang B, Liao M, Meng T, Zhou Y, Chen H.
    Aging (Albany NY); 2021 Jul 21; 13(14):18191-18222. PubMed ID: 34289449
    [Abstract] [Full Text] [Related]

  • 14. A natural antisense lncRNA controls breast cancer progression by promoting tumor suppressor gene mRNA stability.
    Jadaliha M, Gholamalamdari O, Tang W, Zhang Y, Petracovici A, Hao Q, Tariq A, Kim TG, Holton SE, Singh DK, Li XL, Freier SM, Ambs S, Bhargava R, Lal A, Prasanth SG, Ma J, Prasanth KV.
    PLoS Genet; 2018 Nov 21; 14(11):e1007802. PubMed ID: 30496290
    [Abstract] [Full Text] [Related]

  • 15. MYBL2-induced PITPNA-AS1 upregulates SIK2 to exert oncogenic function in triple-negative breast cancer through miR-520d-5p and DDX54.
    Liu B, Yao P, Xiao F, Guo J, Wu L, Yang Y.
    J Transl Med; 2021 Aug 05; 19(1):333. PubMed ID: 34353336
    [Abstract] [Full Text] [Related]

  • 16. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA.
    Luo N, Zhang K, Li X, Hu Y.
    J Cell Biochem; 2020 Oct 05; 121(10):4176-4187. PubMed ID: 31922280
    [Abstract] [Full Text] [Related]

  • 17. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.
    Breast Cancer Res; 2015 Oct 05; 17():19. PubMed ID: 25837326
    [Abstract] [Full Text] [Related]

  • 18. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R, Ortega Gómez A, Hidalgo Miranda A, Zentella Dehesa A, Villarreal-Garza C, Ávila-Moreno F, Arrieta O.
    Clin Epigenetics; 2018 Oct 05; 10():88. PubMed ID: 29983835
    [Abstract] [Full Text] [Related]

  • 19. Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy.
    Jiang T, Zhu J, Jiang S, Chen Z, Xu P, Gong R, Zhong C, Cheng Y, Sun X, Yi W, Yang J, Zhou W, Cheng Y.
    Adv Sci (Weinh); 2023 Jun 05; 10(17):e2207257. PubMed ID: 37096846
    [Abstract] [Full Text] [Related]

  • 20. Deciphering the oncogenic landscape: Unveiling the molecular machinery and clinical significance of LncRNA TMPO-AS1 in human cancers.
    Saraswat SK, Mahmood BS, Ajila F, Kareem DS, Alwan M, Athab ZH, Shaier JB, Hosseinifard SR.
    Pathol Res Pract; 2024 Mar 05; 255():155190. PubMed ID: 38330619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.